Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Imam, H.
Right arrow Articles by Öberg, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Imam, H.
Right arrow Articles by Öberg, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:295-300, 2000
© 2000 European Society for Medical Oncology

research-article

Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours

H. Imam, B. Eriksson and K. Öberg

Department of Internal medicine, University Hospital Uppsala, Sweden

Correspondence to: Prof. K. Öberg, Department of Internal Medicine, University Hospital, S-751 85, Uppsala, Sweden. E-mail. Kjell.Oberg{at}medicin.uu.se

Background: The expression of CD44 and its isoforms have been shown in many neoplastic tissues to serve as prognostic indicators, therefore, the feasibility of using these as prognostic markers in endocrine pancreatic tumour patients was examined.

Patients and methods: Immunohistochemistry (IHC) was performed on 26 tumour samples (5 gastrinomas, 3 glucago-nomas, 10 non-functioning tumours, 6 insulinomas, 2 mixed insulinoma and glucagonomas) with monoclonal antibodies against CD44s (standard form) and variant isoforms (v4, v5, v6, v7, v7-8, v9, vlO). Staining was correlated to the tumour proliferation, malignancy, metastasis and patients survival.

Results: There was variable expression of CD44s. All tumours showed complex expression of many isoforms. CD44v6 and CD44v9 were down regulated in malignant tumours. There was statistical significance of CD44v6 expression in benign tumours (P < 0.05) compared to malignant tumours and near significance in CD44v9 expression (P = 0.0574). Survival of the patients with CD44v6 positive staining was higher than those who were negative (P = 0.0822). Moreover, the expression was well correlated to the patients without any distant metastases (CD44v6, p< 0.001; CD44v9, P < 0.01). Tumour proliferation (Ki67 index) correlated directly to the malignancy (P < 0.05) and there was inverse correlation between Ki67 index and CD44v6 (P< 0.05) as well as v9 (P < 0.05).

Conclusions: Endocrine pancreatic tumours express CD44s and isoforms differentially. Expression of the two isoforms of CD44, namely v6 and v9 seem to be related more to benign form of the tumour and could serve as a predictor of good prognosis.

CD44 isoforms, endocrine pancreatic tumour, immunohistochemistry, tumour proliferation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
T. R Halfdanarson, J. Rubin, M. B Farnell, C. S Grant, and G. M Petersen
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors
Endocr. Relat. Cancer, June 1, 2008; 15(2): 409 - 427.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.